Bicara Therapeutics - BCAX Operating profit EBITDA
Is it worth investing in innovative antibodies that attack tumors from within? The consolidated EBITDA provides the answer, with the latest parameter standing at 0.00. The Bicara Therapeutics Inc. (BCAX) model relies on outsourced drug manufacturing to avoid capital expenditures. While development focuses on head and neck cancer therapy, business growth currently depends entirely on FDA verdicts.
Bicara Therapeutics (BCAX) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Bicara Therapeutics Inc.|BCAX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Bicara Therapeutics Inc|BCAX - Company Aggregate Debts|Debt to Book Value Bicara Therapeutics|BCAX - Company Long-Term Debts|Company Short-Term Debts Bicara Therapeutics|Intermediate Coverage Ratio bicara.com
- earnings and market ratios statistics:
BCAX - Net Profit|Projected Future Earnings Bicara Therapeutics Inc.|BCAX - Price to Earnings Ratio|Future Price to Earnings Multiple bicara.com|BCAX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Bicara Therapeutics|BCAX - Operating profit EBITDA|Earnings per share for the trailing year Bicara Therapeutics|BCAX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months bicara.com|BCAX - Earnings per share growth in current year|Expected earnings per share trend next year Bicara Therapeutics Inc.
- sales revenue and business income indicators:
Summary company analytics:BCAX - Bicara Corp
This indicator reflects the actual cash flow from operating activities before deducting financial expenses and depreciation. By analyzing earnings before interest, taxes, depreciation, and amortization, the investor assesses the business's ability to generate liquidity regardless of its debt load. The metric aggregates operating income and non-cash charges, excluding the impact of the tax regime. Positive dynamics confirm the effective management of the ficlatuzumab clinical pipeline. The high scientific expertise of Bicara Therapeutics Inc. (BCAX) management ensures transparent capital deployment.
Who Bicara Therapeutics Inc. competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Personalis Genomics PSNL|Operating profit EBITDA ERAS|Profit before payment of interest, taxes and amortization DCTH (delcath.com)|Operating profit EBITDA YMAB (Y-mAbs Therapeutics, Inc.)|Operating income before deduction of amortization Aura Biosciences Inc (AURA)|Candel - Operating profit EBITDA|Accuray, Inc. (ARAY) - Operating profit before deduction of amortization|SLS: Operating profit EBITDA|actuatetherapeutics.com (ACTU) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Citius Oncology|HURA: Income before deduction of interest, taxes and amortization|Operating profit EBITDA TARA|Operating profit EBITDA Fate Pharma (FATE)|Aadi Bioscience - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TCRX|CSBR: Operating profit before deduction of amortization|XBiotech Inc. - Company profit before taxes, interest and amortization|CVM: Operating profit EBITDA|OS Therapies, Inc. - Income before deduction of interest, taxes and amortization|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Profit before interest, taxes and amortization Artiva ARTV|Profit before payment of interest, taxes and amortization Adlai Nortye Ltd. (ANL)|VERU (Veru Inc) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TPST (Tempest Tx)|Operating profit EBITDA Xilio Therapeutics Inc XLO|RENB - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization MURA|KAPA: Operating profit EBITDA|Profit before interest, taxes and amortization OnKure Therapeutics (OKUR)|Operating profit before deduction of amortization GDTC|Operating profit EBITDA Curis Corp|Operating profit before deduction of amortization APLM (Apollomics, Inc.)|Company profit before taxes, interest and amortization THAR|Operating profit EBITDA ADVB (Advanced Biomed)|Operating income before deduction of amortization Genprex Inc. (GNPX)|Calidi Bio - Operating profit EBITDA|sunshinebiopharma.com (SBFM) - Operating profit before deduction of amortization|xeneticbio.com (XBIO) - Profit before payment of interest, taxes and amortization|SLRX - Operating income before deduction of amortization|Operating profit before deduction of amortization PPBT|AONC: Income before deduction of interest, taxes and amortization|Operating profit EBITDA BGNE|Operating income before deduction of amortization Checkpoint Therapeutics Inc|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|ICAD: Operating profit before amortization|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX (viracta.com) - Operating profit before deduction of amortization|MOR - Operating income before deduction of amortization|NAYA (NAYA Biosciences) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization AAPGV
